Treatment of idiopathic pulmonary fibrosis in Australia and New Zealand: A position statement from the Thoracic Society of Australia and New Zealand and the Lung Foundation Australia

AuthorsJo, H.E.
Troy, L.K.
Keir, G.
Chambers, D.C.
Holland, A.
Goh, N.
Wilsher, M.
de Boer, S.
Moodley, Y.
Grainge, C.
Whitford, H.
Chapman, S.
Reynolds, P.N.
Glaspole, I.
Beatson, D.
Jones, L.
Hopkins, P.
Corte, T.J.
TypePosition Statement
JournalRespirology
PubMed ID28845557
Year of Publication2018
URLhttps://www.ncbi.nlm.nih.gov/pubmed/28845557
DOI/10.1111/resp.13146
Download Jo_et_al-2017-Respirology.pdf (495.9 KB)
AbstractIdiopathic pulmonary fibrosis (IPF) is a fibrosing interstitial lung disease (ILD) of unknown aetiology with a median survival of only 2-5 years. It is characterized by progressive dyspnoea and worsening lung function, ultimately resulting in death. Until recently, there were no effective therapies for IPF; however, with the publication of two landmark clinical trials in 2014, the anti-fibrotic therapies, nintedanib and pirfenidone, have gained widespread approval. This position paper aims to highlight the current evidence for the treatment of IPF, with particular application to the Australian and New Zealand population. We also consider areas in which evidence is currently lacking, especially with regard to the broader IPF severity spectrum and treatment of co-morbid conditions. The utility of non-pharmacological therapies including pulmonary rehabilitation, oxygen as well as symptom management thought to be important in the holistic care of IPF patients are also discussed.

http://www.ibas.org.au/what-we-do/publications/3872987


< More publications



CHEST-MND:PROCHEST-MND:PRO

Motor neurone disease (MND) causes the body's muscles to weaken. Breathing muscle weakness means that most people affected by MND will eventually lose the ability to take a deep breath and cough strongly....

Respiratory Biomarkers in Motor Neurone DiseaseRESPIRATORY BIOMARKERS IN MOTOR NEURONE DISEASE

The inability to breathe is unfortunately the most common cause of death in people living with Motor Neurone Disease (MND). Last year, our clinical research group in Melbourne reported that breathing...

Notch monitoring in sleepNOTCH MONITORING IN SLEEP

Sleep apnea is a condition where breathing is abnormal during sleep. There are two main forms of sleep apnea: obstructive and central. For obstructive sleep apnea, breathing is reduced because the airway...

Better Sleep, Better Life TipsBETTER SLEEP, BETTER LIFE TIPS

For World Sleep Day, Dr. Amy Jordan joined the "Get Cereal" panelists Sam and Matilda to share top tips for better sleep, discussing the vital importance of sleep health and hygiene in a podcast interview.

Recognising research meritRECOGNISING RESEARCH MERIT

Kudos to Dr. Lauren Booker & Dr. Jen Cori on their JOEM publication examining fatigue detection alarms in rural truck drivers. Their study explores the alarms' effectiveness, accuracy, and habituation, offering key insights into fatigue management.

Honoring Excellence in ResearchHONORING EXCELLENCE IN RESEARCH

Congratulations to Prof. Anne Holland and A/Prof. Narelle Cox for being featured in the NHMRC's 10 of the Best - 16th Edition. Their work exemplifies groundbreaking research delivering extraordinary outcomes.

World Sleep Day on 14th March 2025WORLD SLEEP DAY ON 14TH MARCH 2025

The benefits of quality sleep and to acknowledge the issue of sleep problems and their medical, educational, and social aspects as well as the prevention and management of sleep disorders, is promoted on World Sleep Day on the 14th March 2025.

Institute for Breathing and Sleep

Level 5, Harold Stokes Building, Austin Health
145 Studley Road
Heidelberg, Victoria, 3084

(03) 9496 5390

Email Us

Donate